TG Therapeutics, Inc. (TGTX) Stock Price

TGTXStock

$53.97+54.77%52W

Market Cap$8.26B

P/E18.47x

PEG Ratio1.61

Div yield—

Beta1.83

TGTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)46.26%

Price vs S&P 500 (4W)-4.26%

PEG Ratio1.61

VGM Score59.05

P/E Ratio (Annual)18.47x

Book Value / Share (Quarterly)$3.95

P/TBV (Annual)3.26x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)504.86%

Cash Flow / Share (Quarterly)$0.11

Price vs S&P 500 (YTD)69.12%

Gross Margin (TTM)82.37%

Net Profit Margin (TTM)55.22%

EPS (TTM)$2.75

10-Day Avg Trading Volume1.54M

EPS Excl Extra (TTM)$2.75

Revenue Growth (5Y)426.73%

EPS (Annual)$2.77

ROI (Annual)5.01%

Gross Margin (Annual)83.66%

Net Profit Margin (5Y Avg)-2631.07%

Cash / Share (Quarterly)$3.61

P/E Basic Excl Extra (TTM)18.71x

Revenue Growth QoQ (YoY)70.27%

P/E Normalized (Annual)18.47x

ROA (Last FY)4.05%

Revenue Growth TTM (YoY)76.08%

EBITD / Share (TTM)$0.80

ROE (5Y Avg)-112.83%

Operating Margin (TTM)15.91%

Cash Flow / Share (Annual)$-0.26

P/B Ratio13.68x

P/B Ratio (Quarterly)13.92x

Net Income / Employee (Annual)$1,120,700

EV / Revenue (TTM)10.66x

Net Interest Coverage (TTM)5.02x

ROA (TTM)33.59%

EPS Growth QoQ (YoY)-71.45%

EV / EBITDA (TTM)66.96x

EPS Incl Extra (Annual)$2.77

Current Ratio (Annual)6.25x

Quick Ratio (Quarterly)3.72x

3-Month Avg Trading Volume2.22M

52-Week Price Return54.77%

P/E Incl Extra (TTM)18.71x

Revenue / Employee (TTM)$2,003,800

Tangible BV / Share (Quarterly)$1.17

P/S Ratio (Annual)13.40x

Asset Turnover (Annual)0.57x

52-Week High$59.30

Operating Margin (5Y Avg)-2590.34%

EPS Excl Extra (Annual)$2.77

CapEx CAGR (5Y)-9.73%

Tangible BV CAGR (5Y)-2.68%

26-Week Price Return56.16%

Quick Ratio (Annual)5.03x

13-Week Price Return-1.64%

Total Debt / Equity (Annual)1.10x

Current Ratio (Quarterly)4.27x

Enterprise Value$8.52B

Revenue / Share Growth (5Y)393.83%

Asset Turnover (TTM)0.61x

Book Value / Share Growth (5Y)32.23%

Revenue / Employee (Annual)$1,544,600

Pretax Margin (Annual)17.43%

Cash / Share (Annual)$2.00

3-Month Return Std Dev43.97%

Gross Margin (5Y Avg)88.92%

Net Income / Employee (TTM)$1,106,500

ROE (Last FY)10.52%

Net Interest Coverage (Annual)3.71x

EPS Basic Excl Extra (Annual)$2.77

P/FCF (TTM)141.06x

Receivables Turnover (TTM)2.53x

EV / Free Cash Flow (TTM)490.30x

Total Debt / Equity (Quarterly)1.23x

EPS Incl Extra (TTM)$2.75

Receivables Turnover (Annual)3.65x

ROI (TTM)39.92%

P/S Ratio (TTM)10.33x

Pretax Margin (5Y Avg)-2641.92%

Revenue / Share (Annual)$3.82

Tangible BV / Share (Annual)$1.17

Forward P/E26.42x

Price vs S&P 500 (52W)39.24%

P/E Ratio (TTM)18.71x

EPS Growth TTM (YoY)633.73%

Year-to-Date Return81.05%

5-Day Price Return-2.35%

EPS Normalized (Annual)$2.77

ROA (5Y Avg)-48.82%

Net Profit Margin (Annual)72.56%

Month-to-Date Return-3.24%

Cash Flow / Share (TTM)$-0.18

EBITD / Share (Annual)$0.76

Operating Margin (Annual)20.01%

LT Debt / Equity (Annual)1.10x

P/CF (TTM)462.14x

ROI (5Y Avg)-65.52%

P/E Excl Extra (TTM)18.71x

LT Debt / Equity (Quarterly)1.23x

EPS Basic Excl Extra (TTM)$2.75

P/TBV (Quarterly)3.26x

P/B Ratio (Annual)21.07x

Inventory Turnover (TTM)0.93x

Pretax Margin (TTM)12.71%

Book Value / Share (Annual)$1.43

Price vs S&P 500 (13W)-4.33%

Beta1.83x

Revenue / Share (TTM)$5.08

ROE (TTM)72.30%

52-Week Low$26.76

vGradeD

gGradeB

mGradeB

vgmGradeC

TGTX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 3, 2026	$0.44	$0.05	-88.60%(-$0.39)
Q1 2026	May 6, 2026	$0.28	$0.18	-35.09%(-$0.10)
Q4 2025	Feb 26, 2026	$0.33	$0.14	-57.48%(-$0.19)
Q3 2025	Nov 3, 2025	$0.22	$0.16	-26.30%(-$0.06)
Q2 2025	Aug 4, 2025	$0.29	$0.17	-40.85%(-$0.12)

TGTX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.93

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About TG Therapeutics, Inc.

TG Therapeutics is a biopharmaceutical company specializing in B-cell disease treatments, with FDA-approved BRIUMVI (ublituximab-xiiy) for relapsing multiple sclerosis generating revenue primarily in the United States. The company is advancing a pipeline of early-stage therapies including TG-1701 (BTK inhibitor), Azer-Cel (CAR T-cell therapy), and TG-1801 (bispecific antibody) for various B-cell disorders.

TGTX Next Earnings Report

Report dateNov 2, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate$0.26

Revenue estimate$245.45M

Also reporting on Nov 2, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

TGTX Insider Transactions

SellSep 10, 2026
CHARNEY LAURENCE NEIL
Director
Shares: 5,000Value: $274,800

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

KRYSKrystal Biotech, Inc. Common StockBiological Products
TWSTTwist Bioscience Corporation Common StockBiological Products
KYMRKymera Therapeutics, Inc. Common StockBiological Products
ESIElement Solutions Inc.Industrial Chemicals
WLKWestlake CorporationIndustrial Chemicals
NEUNewMarket CorporationIndustrial Chemicals
AXTAAxalta Coating Systems Ltd.Paints & Coatings
EMNEastman Chemical CompanyPlastics & Resins

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.0

Buy

Consensus rating

52-Week Range

Low$26.76

High$59.30